

1/9

g aggaggct**Ag** cgggaaagtg gtgcaggata taatgccgtg cctgcatttc
gtgaaggggg aggagaagga gccgtcgaag gag**AgcAgc** gcggcacgaa gaagctgagc
gaggaggtga agacgacgga gcagaagagg gaggcctgca agtgcatagt gcgcgccacg
aagggcatct ccggtatcaa aaatgaactt gtcgccgagg tccccaagaa gtgcgatatt
aagaccactc tcccgcccat caccgccgac ttcgactgct ccaagatcca aagtactatt
ttcagagggtt actat

GGATTC

caag aaacc**Agc**gg gactatgggtg agagcgctga tgccgtgcct gccgttcgtg
caggggaaag agaaagagcc gtcaaagggg **AgcAgc**cagcg gcgcaaaaag attggacggg
gagacgaaga cggggccgca gaggggtgcac gcttggtgagt gcatccagac cgccatgaag
acttattccg acatcgacgg gaaactcgtc agcgagggtcc ccaagcactg cggcatcgtt
gacagcaagc tcccgcccat tgacgtcaac atggactgca agacagttgg agtggttcct
cggcaacccc aacttccagt ctctctccgt catgggtccc tcacggggccc aagtgatccc
gcccacaaag cacggttgga gagaccccag attagagttc cgccccccgc accggaaaaa
gcc TAA

Fig. 1

2/9

1 50
EEASGKVVQD IMPCLH FVKG EEKEPSKESS SGTKKLSEEV KTTEQKREAC

51 100
KCIVRATKGI SGIKNELVAE VPKKCDIKTT LPPITADFDC SKIQSTIFRG

101 150
YYGFQETSGT MVRALMPCLP FVQGKEKEPS KGSSSGAKRL DGETKTGPQR

151 200
VHACECIQTA MKTYS DIDGK LVSEVPKHCG IVDSKLPPID VNMDCKTVGV

201 243
VPRQPQLPVS LRHGPVTGPS DPAHKARLER PQIRVPPPAP EKA

Fig.2

3/9




FIG. 3





Fig 4

Binding inhibition
ELISA


	Dimer W.T	PjEDcys
Patient 1	68%	7%
Patient 2	56%	3,5%
Patient 3	62%	10%
Patient 4	62%	8%
Patient 5	62%	8%

Fig. 5


6/9




—◇— rPj1+rPj2 Mix — — PjEDcys



—◇— rPj1+rPj2 Mix — — PjEDcys



—◇— rPj1+rPj2 Mix — — PjEDcys



—◇— rPj1+rPj2 Mix — — PjEDcys

Fig. 6




Fig 7

**% of human IgE
binding inhibition**

<i>P. judaica</i> extract	Expj	rParj1	rParj2	rParj1 rParj2
Patient 1	94	10	80	80
Patient 2	93	53	74	74
Patient 3	90	35	37	80
Patient 4	98	59	85	86
Patient 5	100	57	29	67
Patient 6	91	29	65	69
Patient 7	94	38	58	79
Average	94,3	40,1	61,1	76,5

Fig. 8

**% of human IgE
binding inhibition**

tested Protein	% of inhibition
rParj 1	95%
PjA	16%
PjB	85%
PjC	14%
PjD	15%

Fig. 9